MX362061B - Ácidos nucleicos de enlace c5a nuevos. - Google Patents

Ácidos nucleicos de enlace c5a nuevos.

Info

Publication number
MX362061B
MX362061B MX2014008454A MX2014008454A MX362061B MX 362061 B MX362061 B MX 362061B MX 2014008454 A MX2014008454 A MX 2014008454A MX 2014008454 A MX2014008454 A MX 2014008454A MX 362061 B MX362061 B MX 362061B
Authority
MX
Mexico
Prior art keywords
new
nucleic acids
binding nucleic
nucleic acid
acid molecule
Prior art date
Application number
MX2014008454A
Other languages
English (en)
Spanish (es)
Other versions
MX2014008454A (es
Inventor
Höhlig Kai
Vater Axel
Buchner Klaus
Maasch Christian
Klussmann Sven
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of MX2014008454A publication Critical patent/MX2014008454A/es
Publication of MX362061B publication Critical patent/MX362061B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
MX2014008454A 2012-01-10 2013-01-10 Ácidos nucleicos de enlace c5a nuevos. MX362061B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12000106 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12006960 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (2)

Publication Number Publication Date
MX2014008454A MX2014008454A (es) 2015-02-05
MX362061B true MX362061B (es) 2019-01-07

Family

ID=48781063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008454A MX362061B (es) 2012-01-10 2013-01-10 Ácidos nucleicos de enlace c5a nuevos.

Country Status (18)

Country Link
US (5) US9518265B2 (OSRAM)
EP (1) EP2802660B1 (OSRAM)
JP (1) JP6415327B2 (OSRAM)
KR (1) KR102034203B1 (OSRAM)
CN (1) CN104145018B (OSRAM)
AU (2) AU2013209131A1 (OSRAM)
BR (1) BR112014016877B1 (OSRAM)
CA (1) CA2860806C (OSRAM)
DK (1) DK2802660T3 (OSRAM)
ES (1) ES2786007T3 (OSRAM)
IL (1) IL233516B (OSRAM)
IN (1) IN2014DN05665A (OSRAM)
MX (1) MX362061B (OSRAM)
PL (1) PL2802660T3 (OSRAM)
PT (1) PT2802660T (OSRAM)
RU (1) RU2645261C2 (OSRAM)
SG (2) SG10201605594UA (OSRAM)
WO (1) WO2013104540A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928644C (en) 2013-10-28 2021-07-20 Dots Devices, Inc. Allergen detection
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
EP3793427A1 (en) 2018-05-17 2021-03-24 The Procter & Gamble Company Systems and methods for hair coverage analysis
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN112771164A (zh) 2018-06-29 2021-05-07 宝洁公司 用于个人护理应用的适配体
CA3119357A1 (en) 2018-11-12 2020-05-22 Aptarion Biotech Ag Cxcl8 binding nucleic acids
CA3134968A1 (en) 2019-04-16 2020-10-22 Juan Esteban Velasquez Aptamers for odor control applications
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用
EP4620474A1 (en) 2024-03-20 2025-09-24 APTARION biotech AG Method of treating a disorder with a c5a inhibitor
WO2025196240A1 (en) 2024-03-20 2025-09-25 Aptarion Biotech Ag Method of treating a disorder with a c5a inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
WO2003035665A1 (de) 2001-10-26 2003-05-01 Noxxon Pharma Ag Modifizierte l-nukleinsäure
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
AU2003219796A1 (en) 2002-02-20 2003-09-09 Beth Israel Deaconess Medical Center Conjugates comprising a biodegradable polymer and uses therefor
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
CN1917905B (zh) 2004-02-09 2012-01-04 诺松制药股份公司 从多糖和多核苷酸生产缀合物的方法
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
DK2860251T3 (en) 2004-02-12 2018-06-06 Archemix Llc APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel
CN101098703B (zh) 2004-11-05 2011-08-03 费城儿童医院 用于分子治疗的生物降解连接剂
WO2006074964A1 (en) * 2005-01-17 2006-07-20 Jerini Ag C5a receptor antagonists
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
CA2662978A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2061901A2 (en) 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
EP2205734A2 (en) * 2007-09-24 2010-07-14 Noxxon Pharma AG C5a BINDING NUCLEIC ACIDS
CN102421350B (zh) 2009-03-11 2014-12-17 奥林巴斯医疗株式会社 图像处理系统、其外部装置及其图像处理方法
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
CN102906265B (zh) 2010-04-21 2016-08-24 诺松制药股份公司 脂质结合核酸
EP2663640B1 (en) * 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
BR112014009104A2 (pt) 2011-10-21 2017-04-18 Noxxon Pharma Ag ácidos nucleicos que se ligam ao glucagon
US9163243B2 (en) 2012-01-10 2015-10-20 Noxxon Pharma Ag Nucleic acids specifically binding CGRP

Also Published As

Publication number Publication date
DK2802660T3 (da) 2020-05-18
US20140364487A1 (en) 2014-12-11
IN2014DN05665A (OSRAM) 2015-05-15
AU2013209131A1 (en) 2014-07-10
AU2018271388B2 (en) 2021-03-11
US20180223285A1 (en) 2018-08-09
BR112014016877A2 (pt) 2019-10-29
US20240384275A1 (en) 2024-11-21
US11492625B2 (en) 2022-11-08
CA2860806A1 (en) 2013-07-18
ES2786007T3 (es) 2020-10-08
WO2013104540A1 (en) 2013-07-18
AU2018271388A1 (en) 2018-12-20
US10590424B2 (en) 2020-03-17
SG10201605594UA (en) 2016-09-29
MX2014008454A (es) 2015-02-05
PL2802660T3 (pl) 2020-07-27
IL233516B (en) 2018-07-31
US20250327082A1 (en) 2025-10-23
IL233516A0 (en) 2014-08-31
US20210163946A1 (en) 2021-06-03
BR112014016877B1 (pt) 2022-03-15
CA2860806C (en) 2020-10-20
KR20140111703A (ko) 2014-09-19
EP2802660A1 (en) 2014-11-19
EP2802660B1 (en) 2020-02-19
KR102034203B1 (ko) 2019-10-18
HK1198371A1 (en) 2015-04-10
JP2015509705A (ja) 2015-04-02
US12188021B2 (en) 2025-01-07
RU2645261C2 (ru) 2018-02-19
JP6415327B2 (ja) 2018-10-31
US9518265B2 (en) 2016-12-13
CN104145018B (zh) 2019-05-10
PT2802660T (pt) 2020-04-21
SG11201403771SA (en) 2014-07-30
RU2014132708A (ru) 2016-02-27
CN104145018A (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
CY1120685T1 (el) Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
UA118014C2 (uk) Спосіб модифікації днк-мішені
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
MX2011003229A (es) Terapia genica con porfobilinogeno desaminasa.
MX2010003109A (es) Acidos nucleicos de enlace c5a.
MX2013007678A (es) Moleculas de acido nucleico dirigidas ala pequeña proteina de union de gtp rho1 y que confieren resistencia a las plagas de coleopteros.
NZ607870A (en) Lactococcus crispr-cas sequences
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
IN2012DN00403A (OSRAM)
WO2013090457A3 (en) In vivo delivery of oligonucleotides
GB201021867D0 (en) Non-coding immunomodulatory DNA construct
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
EA201101627A1 (ru) Рекомбинантные бактерии и их применение для получения этанола
WO2012046084A3 (en) Short rna molecules
WO2010107955A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
IN2013MN01235A (OSRAM)
ATE536360T1 (de) Neues nukleinsäuretransfersystem
MX377713B (es) Moleculas de ácido ribonucleico pequeño de interferencia especifico de notch 1.
MX2018005146A (es) Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1.
TN2013000498A1 (fr) Constructions d'extinction du gene p0 et utilisation

Legal Events

Date Code Title Description
FG Grant or registration